Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's looking like ARDM is waking up. It was mentioned in the same article as ANX
very nice. Me too Took a small position. Will add into the new year.
I wonder what CTIC technical s looked like before it's meteoric rise? lol
Also worth noting, that in all other attempts to break resistance, there was not nearly as much volume.
Getting ready to take a position with you. Happy Holidays
I am putting this one on watch. Read this PR
Aradigm Announces Third Quarter 2009 Financial Results
Nov 5, 2009 7:00:00 AM
Copyright Business Wire 2009
Email Story Discuss on ZenoBank
View Additional Profiles
Inhaled Liposomal Ciprofloxacin Program is Progressing; Milestone Payment and Royalties Will Be Received Upon Zogenix Planned January 2010 Product Launch
HAYWARD, Calif.--(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced financial results for the third quarter and nine months ended September 30, 2009 and recent highlights.
Revenue for the third quarter of 2009 was $4.9 million, compared to revenue of $0.2 million for the third quarter of 2008. The bridging study fee, milestone payment and research and development reimbursements received in connection with the collaboration with Lung Rx, Inc. ("Lung Rx") for the development of inhaled treprostinil in the AERx(R) delivery system which had previously been recorded as deferred revenue were recognized in the third quarter upon termination of the collaboration by Lung Rx.
Total operating expenses for the third quarter of 2009 were $5.4 million, compared to total operating expenses of $4.8 million for the third quarter of 2008. The increase in operating expenses resulted from the Company recording, in accordance with generally accepted accounting principles, $1.6 million in asset impairment expense associated with the Lung Rx collaboration termination to reflect the idle state of AERx production fixed assets. The partially offsetting decrease in operating expenses was due to cost control efforts. The Company's net loss for the third quarter of 2009 was $0.6 million, or $0.01 per share, compared to a net loss of $4.6 million, or $0.08 per share, for the third quarter of 2008.
As of September 30, 2009, cash, cash equivalents and short-term investments totaled $11.8 million.
Recent Highlights
-- Final preparations for the initiation of the Phase 2b program to
evaluate the Company's once-daily inhaled liposomal ciprofloxacin
administered via nebulizer in patients with non-cystic fibrosis
bronchiectasis are progressing, with international regulatory,
institutional review board and ethics committee approvals being
completed and site initiation underway. This orphan drug condition is a
chronic severe respiratory disease and there is currently no drug
specifically approved for its treatment in the U.S.
-- The Company will be entitled to a $4.0 million milestone payment upon
initial U.S. commercialization by Zogenix, Inc. ("Zogenix") of SUMAVEL*
DosePro* needle-free delivery system, as well as royalty payments upon
sales of DosePro products. Zogenix announced that it had completed a $51
million preferred stock financing, with the capital to be used to
finance the January 2010 planned launch of SUMAVEL DosePro. Zogenix and
its European partner, Desitin Pharmaceuticals, GmbH ("Desitin"),
announced that Desitin has filed for European regulatory approval of
SUMAVEL DosePro following the successful completion of a European
pivotal bioequivalence trial.
"We are very pleased that the first product using the needle-free DosePro technology is now ready for commercialization in the U.S. by Zogenix and its partner, Astellas Pharma US, Inc. We are continuing in our efforts to seek new collaborations utilizing our AERx technology platform and to generate non-dilutive financing by monetizing our non-strategic assets, while focusing on the development of inhaled liposomal ciprofloxacin for the prevention and treatment of infections associated with severe respiratory diseases," said Igor Gonda, the Company's CEO and President.
About Aradigm
Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. The Company has product candidates addressing the treatment of cystic fibrosis, bronchiectasis, inhalation anthrax infections and smoking cessation.
Aradigm, AERx, and the Aradigm Logo are registered trademarks of Aradigm Corporation.
* Other names and brands may be claimed as the property of others.
More information about Aradigm can be found at www.aradigm.com.
Forward-Looking Statements
Except for the historical information contained herein, this news release contains forward-looking statements, including statements regarding royalty payments upon commercialization of SUMAVEL DosePro products. These forward-looking statements involve risk and uncertainties, including the advancement of product development, commercialization efforts, status of collaboration arrangements and the ability to successfully manage and preserve cash, as well as the other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2008 files with the SEC on March 30, 2009, and the Company's Quarterly Reports on Form 10-Q.
ARADIGM CORPORATION
CONDENSED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)
Three months ended Nine months ended
September 30, September 30,
2009 2008 2009 2008
We broke .206 ANX Get it going already. hehehehehehehehehe
Best of luck to you this holiday. I hope all goes well for you.
I hate to hear bad news. We will send a prayer from Rhode Island.
I think so as well. We are gonna need ANX to speak up here soon. The speculative money will stop flowing in if they don't make a sound.
IMO
I am hoping. How goes things Glassy? good to hear from you.
I am in ANX @ .17 Waiting for it to do what ATHX did this am.
That would be very merry indeed. hehehehehehe
I agree. There are some real knuckleheads over on the Yahoo board. lol
ANX The real deal Million.
Hey check out ATHX lol
did u buy the dip on ATHX??
ANX going according to plan
indeed
Morning. Look @ ATHX we missed that bugger. just inked a deal w/ phizyer. ut 120% pre mkt.
This PR came out on sat. Folks don't miss this ride.
ANX buy-buy-buy
(RTTNews) - Within the next few days, Adventrx Pharmaceuticals Inc. (ANX: News ) is expected to submit its New Drug Application for ANX-530, a novel emulsion formulation of chemotherapy drug Navelbine (vinorelbine). If submitted, the filing will mark the first NDA submission for Adventrx' drug.
Navelbine, a branded formulation of vinorelbine, is approved in the U.S. to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, and approved in the European Union to treat non-small cell lung cancer and advanced or metastatic breast cancer. According to the company, Navelbine, which, despite being a generic product for a number of years, still sells in excess of $200 million a year world-wide. Adventrx is planning to seek approval of ANX-530 for the same indications as Navelbine.
Adventrx has yet another late-stage product candidate ANX-514 (docetaxel emulsion for injection), a reformulation of the blockbuster chemotherapeutic agent, Taxotere.
Incorporated under the name Victoria Enterprises, Inc. in December 1995, the company began operations in 1996. The name was subsequently changed to "BioQuest, Inc." then to "Biokeys Pharmaceuticals, Inc." and finally to "ADVENTRX Pharmaceuticals, Inc." in May 2003. The company's common stock trades on the American Stock Exchange (Amex).
No prediction. only hoping it goes alot higher. There is alot of MOMO right now. We got some pre mkt action.
Best of luck to ya
better days ahead my friends. The pump is in full swing. With teeth to back it up.
Happy Holidays Durk, U might want to grab a position in ANX
check it out.
not a short squeeze. bio-stock
Thanks for the link. We sure are getting some great exposure.
Look me up General. I play on pokerstars. greggor62
I think you are right. This got got way too cheap, and we are sitting in a good position here.
Good luck in Vegas
TIC-TOC no shoes. TIC-TOC hehehehehehehe
Heres another article on ANX last night.
http://www.transworldnews.com/NewsStory.aspx?StoryID=149507
we are getting noticed big time
Very nice job on the airlines. good call.
Homosapian.
VIENS
Hey big guy. Happy happy
ANX
Happy Holidays Disposable one
I am in ANX @ .17 heres a read for ya
http://www.adventrx.com/assets/pdfs/ANX-TWST-Oct09-FINAL.pdf
Heres a very nice read on ANX
http://www.adventrx.com/assets/pdfs/ANX-TWST-Oct09-FINAL.pdf
Heres a nice read and a snapshot.
http://www.adventrx.com/assets/pdfs/ANX-TWST-Oct09-FINAL.pdf
Careful, you don't get your car stolen at the mall. lol
Have a good 1. excellent week
And remember to keep the ARTS on your watch list.
a good day overall. very bullish
back in the 18's here we go gents
She's gonna blow
oh yes. GETA rockin
I will buy some ARTS down here cheap. it will have a turn soon
GETA going off. up 65% yesterday up .025c pre mkt
NEXM running pre mkt.
Good for you Tommy. Shoot em up.
PR just out on ANX. biomed reports is pumping hard
Lets go baby
Nice link.
ARTS is a buy too. .024
No kidding. I have seen enough on the history channel about our planet over the last year to realize there are greater forces that control our fate.
Like the Mayan calender. lmao. ha-ha
Still a big move, considering it's yearly trading range.
Heres to higher lows. lol
Cold Merry Christmas from New England. lol I'm not liking these teens tempatures.
And the same to you sir.
ARTS just crossed my radar. any thoughts?